The Hypothesis

I suggest that the progression from sub-lethal lysosomal membrane permeabilization (LMP) to catastrophic cellular damage isn't just about increased leakage; it’s a failure of the Cystatin-PITT (Phosphoinositide-3-phosphate-dependent lysosomal repair) signaling axis. I hypothesize that the age-related decline of Cystatin B represents a failure of "enzymatic titration." When cytoplasmic Cystatin B drops below a critical stoichiometric threshold, the transient, reversible LMP events usually fixed by the PITT pathway undergo a phase transition into chronic inflammasome activation.

Mechanistic Insight

While the PITT pathway is known as a repair mechanism, current models don’t explain why this efficiency wanes over time. My hypothesis is that leaked Cathepsin D and B aren’t just hitting distal targets like caspases or NLRP3; they are actively digesting the endosomal sorting complexes required for PITT recruitment.

1. The Stoichiometric Mismatch: In younger cells, Cystatin B acts as a cytoplasmic buffer. During minor LMP, the inhibitor quickly binds escaping cathepsins, stopping them from degrading the ESCRT/PITT machinery needed for membrane resealing.
2. The Catalytic Feedback Loop: As Cystatin B levels drop with age, that "cytoplasmic cathepsin buffer" vanishes. Unrestrained cytoplasmic cathepsins then proteolytically cleave Annexins and ESCRT proteins, which physically prevents the PITT pathway from fixing the initial breach.
3. From Repair to Damage: This turns a repairable fluctuation into a permanent, widening pore. The shift from transient LMP to persistent lysosomal membrane rupture (LMR) is a function of the local concentration of unbound Cathepsin B/D relative to the availability of repair-complex proteins, which are being degraded by those very cathepsins.

Experimental Testability

This hypothesis offers a clear, falsifiable framework:

• Quantitative Thresholding: By using CRISPR-Cas9 to titrate Cystatin B levels in iPSC-derived neurons, we can see if there’s a non-linear “cliff” in repair efficacy. If I’m right, PITT-mediated repair should drop off sharply once Cystatin B levels fall below the amount needed to neutralize a standard “leak burst.”
• Proteomic Fate of PITT: We can use FRET-based biosensors to watch the degradation of ESCRT-III proteins (like CHMP4B) in real-time after inducing LMP under both low and high Cystatin B conditions.
• Therapeutic Potential: If this loop is real, our goal changes: we shouldn't just aim to stop LMP—a difficult target—but to pharmacologically replenish Cystatin B or use non-degradable synthetic cathepsin inhibitors to preserve the repair machinery. This would allow the cell to "reset" its lysosomal membrane integrity, effectively decoupling age-related lipofuscin accumulation from neurodegeneration.

This “Slow Burn” model shifts the focus from the leak itself to the enzymatic failure of the rescue mechanism. It suggests that neurodegeneration isn't caused by the leaked cathepsins alone, but by the loss of the feedback mechanism that keeps them in check.